FDA DEVICE FACTS
RadOncAI
Informai
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
RadOncAI is indicated for use in a clinical setting by radiation oncologists, medical physicists, and dosimetrists to configure and review radiotherapy treatment plans for adult patients with malignant or benign head-and-neck disease. The software accepts: * A CT-simulation scan * Clinician-defined planning target volumes * Clinician-supplied data on organs at risk (OARs) Using these inputs, RadOncAI generates a patient-specific preliminary dose distribution that includes: * Estimated achievable dose coverage of the planning target volume(s) * Estimated achievable sparing of surrounding OARs The directive derived from the AI-generated plan must be reviewed, revised, and approved by a qualified professional before clinical implementation. The AI-generated dose distribution must be transferred to a compatible radiotherapy treatment-planning system or reviewed using DICOM-RT-compliant software before further use in clinical workflows. RadOncAI is not intended for primary diagnosis, autonomous clinical decision-making, delivery of radiation, or use in patient populations, anatomical sites, or treatment modalities outside the indications stated above.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。